Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.06, Zacks reports. Sonnet BioTherapeutics had a negative return on equity of 382.31% and a negative net margin of 11,187.19%.
Sonnet BioTherapeutics Stock Performance
NASDAQ SONN opened at $0.66 on Friday. Sonnet BioTherapeutics has a 12 month low of $0.62 and a 12 month high of $8.19. The company’s 50 day moving average is $0.99 and its two-hundred day moving average is $1.50.
Analyst Upgrades and Downgrades
Separately, Chardan Capital restated a “buy” rating and set a $30.00 target price on shares of Sonnet BioTherapeutics in a research note on Tuesday, May 28th.
Sonnet BioTherapeutics Company Profile
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Featured Articles
- Five stocks we like better than Sonnet BioTherapeutics
- How to Use the MarketBeat Stock Screener
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 8/12 – 8/16
- Insider Trading – What You Need to Know
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
